Jessamyn Fairfield

speaker

401 appearances 5 recordings 1 series first heard Apr 2026 last heard 30 Aug

Jessamyn Fairfield’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

Recordings per month over the last 12 months — 5 in all, peaking in Jul 2026 with 2.

Appearances

newest first · ▶ plays the moment

Futureproof with Jonathan McCrea · What happens when you're struck by lightning? · 21 Jun 2026 podcast

So lupus, if you're not familiar, is this chronic autoimmune disease.

It affects about 5 million people worldwide, and it's a really nasty piece of work.

It's where your immune system basically attacks healthy tissue, which can result in lots of inflammation, fatigue, but also damage to your internal organs, like your kidneys, your lungs, your heart.

It's a really, really...

a bad disease and a disease that's quite hard to treat as well because if you think about you know for very severe cases of lupus how could you reduce the sort of immune activity in your body if you reduce the thing that is causing lupus you then also reduce your immune system and its ability to respond to other stuff so

It's been a really persistent and difficult disease to treat for a long time.

But this new kind of therapy that was trialed in a study by University College London and the NHS in the UK actually found incredibly good response using this new immunotherapy.

So it's a type of therapy that's actually already been used to treat different types of blood cancers.

And basically what they do is they take your T cells, so these immune cells in the body, they take some of them out.

And they teach them how to identify some of the like rogue B cells or the rogue immune cells that are causing the lupus itself.

Yeah.

They take them out.

They sort of reprogram them.

They put them back in.

And one thing that's amazing about this treatment is that it's a one time treatment.

It's not like a medication that you have to take.

It's not an ongoing thing.

It is a one-time reinfusion of these modified T cells.

It's called CAR T cell therapy.

So the CAR is chimeric antigen receptors, which is the type of change that they're providing to the T cells.

Showing 241–260 of 401 · page 13 of 21